ADAG
Price
$1.48Alerts
Change
-$0.12 (-7.50%)
Updated
Nov 17, 04:59 PM (EDT)
Capitalization
134.29M
15 days until earnings call
Intraday BUY SELL Signals
BNTC
Price
$8.13Alerts
Change
-$0.41 (-4.80%)
Updated
Nov 17, 04:59 PM (EDT)
Capitalization
332.78M
Intraday BUY SELL Signals
Interact to see
Advertisement

ADAG vs BNTC

ADAG vs BNTC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ADAG vs. BNTC commentary
Nov 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAG is a Hold and BNTC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ADAG with price predictions
Nov 16, 2026

ADAG in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026

ADAG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 50 of 52 cases where ADAG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADAG advanced for three days, in 181 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADAG as a result. In 91 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for ADAG turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 45 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 50-day moving average for ADAG moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADAG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ADAG entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.501) is normal, around the industry mean (3.586). P/E Ratio (-5.333) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (17.606) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ADAG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADAG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for BNTC with price predictions
Nov 16, 2026

BNTC's RSI Oscillator climbs out of oversold territory

The RSI Indicator for BNTC moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 21 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BNTC as a result. In 86 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for BNTC just turned positive on October 20, 2026. Looking at past instances where BNTC's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.

Following a +14.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTC advanced for three days, in 226 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 116 of 145 cases where BNTC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 46 cases where BNTC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

BNTC broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. BNTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.880) is normal, around the industry mean (3.586). P/E Ratio (-9.735) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. BNTC's P/S Ratio (2500.000) is slightly higher than the industry average of (440.869).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BNTC: Fundamental Ratings
BNTC
OUTLOOK RATING
1..100
27
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
21
SEASONALITY SCORE
1..100
8

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ADAGBNTC
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 14 days ago
85%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
COMPARISON
Comparison
Nov 17, 2026
Stock price -- (ADAG: $1.60 vs. BNTC: $8.54)
Brand notoriety: ADAG and BNTC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAG: 346% vs. BNTC: 73%
Market capitalization -- ADAG: $134.29M vs. BNTC: $332.78M
ADAG [@Biotechnology] is valued at $134.29M. BNTC’s [@Biotechnology] market capitalization is $332.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAG’s FA Score shows that 2 FA rating(s) are green while BNTC’s FA Score has 1 green FA rating(s).

  • ADAG’s FA Score: 2 green, 3 red.
  • BNTC’s FA Score: 1 green, 4 red.
According to our system of comparison, ADAG is a better buy in the long-term than BNTC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAG’s TA Score shows that 4 TA indicator(s) are bullish while BNTC’s TA Score has 5 bullish TA indicator(s).

  • ADAG’s TA Score: 4 bullish, 5 bearish.
  • BNTC’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BNTC is a better buy in the short-term than ADAG.

Price Growth

ADAG (@Biotechnology) experienced а -24.53% price change this week, while BNTC (@Biotechnology) price change was -13.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.73%. For the same industry, the average monthly price growth was -7.91%, and the average quarterly price growth was -21.89%.

Reported Earning Dates

ADAG is expected to report earnings on Dec 02, 2026.

Industries' Descriptions

@Biotechnology (-9.73% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ADAG and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAG has been loosely correlated with CYTK. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAG jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAG
1D Price
Change %
ADAG100%
-6.43%
CYTK - ADAG
34%
Loosely correlated
-5.27%
OCGN - ADAG
33%
Poorly correlated
-6.62%
DNLI - ADAG
32%
Poorly correlated
-3.52%
SLDB - ADAG
31%
Poorly correlated
-5.26%
BNTC - ADAG
30%
Poorly correlated
-5.53%
More

BNTC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BNTC has been loosely correlated with SLDB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTC jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTC
1D Price
Change %
BNTC100%
-5.53%
SLDB - BNTC
53%
Loosely correlated
-5.26%
KYTX - BNTC
52%
Loosely correlated
-5.74%
TSHA - BNTC
51%
Loosely correlated
-0.98%
VIR - BNTC
51%
Loosely correlated
-3.82%
MGTX - BNTC
49%
Loosely correlated
-4.79%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FBND43.700.02
+0.05%
Fidelity Total Bond ETF (FBND)
BTO37.34-0.22
-0.59%
John Hancock Financial Opportunities Fund
MLPB28.21-0.36
-1.25%
ETRACS Alerian MLP Infrastructure Index ETN Series B (MLPB)
MCHS33.41-0.62
-1.82%
Matthews China Innovators Active ETF (MCHS)
XITK178.81-4.68
-2.55%
State Street SPDR FactSet Innovative Technology ETF (XITK)